Full Text View
Tabular View
No Study Results Posted
Related Studies
The Safety and Tolerability of Alpha-1 MP In Subjects With Alpha-1-Antitrypsin (AAT) Deficiency (STAMP)
This study has been completed.
Study NCT00301366   Information provided by Grifols Therapeutics Inc.

First Received on March 8, 2006.   Last Updated on September 26, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alpha 1-Antitrypsin Deficiency
More general conditions related to this trial
Digestive System Diseases
Emphysema
Genetic Diseases, Inborn
Liver Diseases
Lung Diseases
Pathologic Processes
Respiratory Tract Diseases
Subcutaneous Emphysema
Additional drug interventions recognized in this trial
Alpha 1-Antitrypsin
Protease Inhibitors
Protein C Inhibitor
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serine Proteinase Inhibitors
Trypsin Inhibitors
Sponsors listed in this trial
Grifols Therapeutics Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services